Pfizer Inc.

-1.28 (-2.37%)
5:00:57 PM EDT: $52.60 -0.17 (-0.32%)
Products, Regulatory

Pfizer Says Received Positive Opinion From European Medicines Agency's CHMP for LORVIQUA (lorlatinib)

Published: 12/17/2021 10:13 GMT
Pfizer Inc. (PFE) - Pfizer Receives Positive Chmp Opinion for Lorviqua® (lorlatinib) As First-line Treatment for Alk-positive Advanced Lung Cancer.
Recommendation Based on Results From the Phase 3 Crown Trial.
Trial Showed Lorviqua Reduced Risk of Cancer Progression Or Death by 72% in Newly Diagnosed Individuals Compared to Xalkori® (crizotinib).
Pfizer- Chmp of Ema Has Adopted Positive Opinion Recommending Lorviqua Available in U.S. Under the Brand Name Lorbrena®) for Marketing Authorization.
The Chmp’s Opinion Will Now Be Verified by the European Commission With a Decision Expected in the Coming Months.
Positive Chmp Opinion of Lorviqua Follows the Medicine’s Approval by the U.S. Food and Drug Administration (fda) in March 2021.
Further Company Coverage: .